Protocol Ledger

NCT04071366 · Phase II · COMPLETED

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Interventional Phase II clinical trial protocol NCT04071366 sponsored by Incyte in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-07 Enrollment: 112 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04071366
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)112 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04071366
Protocol FieldVerified Registry Value
NCT IdentifierNCT04071366
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment112 participants (ACTUAL)
Registered Start Date2020-02-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI